A potential explanation for this phenomenon is that enzymes adding O-fucose to proteins localize to cell organelles other than the Golgi apparatus. In this study, we investigated the subcellular localization of protein Of u c o s y l t r a n s f e r a s e 1 ( O -F u c T-1), responsible for adding O-fucose to EGF repeats. Our analysis reveals that, unlike all other known fucosyltransferases, O-FucT-1 is a soluble protein that localizes to the ER. In addition, it appears that O-FucT-1 is retained in the ER by a KDEL-like sequence at its C-terminus. Our results also suggest that enzymatic addition of O-fucose to proteins occurs in the ER, suggesting that a novel, ER localized GDP-fucose transporter may exist. The fact that OFucT-1 recognizes properly folded EGF repeats, together with this unique localization, suggests that it may play a role in quality control.
Fucose is a common component of many N-linked and O-linked glycans found on glycoproteins in metazoans (1) . It is involved in a variety of critical physiological processes, such as selectin-mediated leukocyteendothelial adhesion (2) , ABO blood type antigen determination (3) , and Notch receptor signaling (4, 5) . Fucose modification is catalyzed by fucosyltransferases, all of which require GDP-fucose as the donor substrate and a glycan or protein as the acceptor substrate. Currently known fucosyltransferases in mammals can be classified into four groups based on specific linkages formed and substrates to which fucose is added (1) . The first group include the a2 fucosyltransferases that modify the terminal Gal moiety of lactosamine structures with a1,2 linked fucose (FUT1, 2). The second group is the a 3 / 4 fucosyltransferases that add fucose in a1,3/4 linkage to the GlcNAc moiety of lactosamine structures (FUT3-7 and 9). a 6 fucosyltransferase which adds fucose in a1, 6 linkage to the first GlcNAc of the N-glycan core is the unique member of the third group (FUT8). Finally, the fourth group consists of protein O-fucosyltransferases 1 and 2 (OFucT-1 and O-FucT-2), the most recent additions to the fucosyltransferase family.
Sequence alignment reveals that the protein O-fucosyltransferases share a common ancestry with both a 2 and a 6 fucosyltransferases (6) . Nonetheless, O-FucT-1 and O-FucT-2 share several biochemical properties that distinguish them from other known fucosyltransferases (7-9) (Luo and Haltiwanger, manuscript in preparation). For instance, both enzymes catalyze the addition of fucose directly to a serine or threonine in proteins instead of to another sugar. For both enzymes, the modified serine or threonine occurs in the context of a cysteine knot motif: epidermal growth factor-like (EGF) repeats for O-FucT-1, and thrombospondin type 1 repeats (TSR) for O-FucT-2. EGF repeats are defined by the presence of six conserved cysteine residues forming three disulfide bonds in a specific pattern: C 1 -C 3 , C 2 -C 4 , C 5 -C 6 (10) . The O-fucose modifies a serine or threonine adjacent to the third conserved cysteine within the consensus sequence C 2 X 4-5 (S/T)C 3 (11) . O-FucT-1 has been shown to add O-fucose to EGF-like repeats from a variety of proteins including the Notch receptor (12) . Reduction or elimination of O-FucT-1 levels using gene ablation in mice or RNAi or mutants in Drosophila suggests that O-FucT-1 is essential for Notch signaling (13) (14) (15) . In vitro binding studies suggest that the O-fucose plays an essential role in ligand binding, offering a potential explanation for the essential nature of O-FucT-1 (16) .
TSRs also contain six conserved cysteines forming three disulfide bonds in a distinct pattern: (17) . Although a consensus sequence for O-fucose on TSRs has been proposed (WX 5 C 1 X 2/3 S/TC 2 X 2 G) (18), little is known about the functional importance of this modification.
The biological significance of fucosylation in humans has been made clear by studies of a rare autosomal recessive human disease called LADII (Leukocyte Adhesion Deficiency)/CDG IIc, which is characterized by leukocyte adhesion deficiency as well as severe neurological and developmental abnormalities (19) . The molecular defect in LADII/CDG IIc has been identified as mutations in the Golgi GDPfucose transporter, resulting in decreased GDP-fucose levels in the Golgi lumen and, hence, reduction of fucosylated antigens on the cell surface (20) (21) (22) (23) . Because Notch signaling is critical to numerous developmental processes in mammals, we had speculated that the neurologic and developmental symptoms of LADII/CDG IIc patients might be linked to impaired Notch signaling due to insufficient GDP-fucose in the Golgi lumen (24, 25) . A recent study using fibroblasts from LADII/CDG IIc patients suggested that while terminal fucosylation of N-glycans is reduced severely, protein Ofucosylation is generally unaffected (26) . The authors proposed two potential explanations for this surprising result. One possibility is that O-fucosyltransferases have higher affinity for GDP-fucose than those adding terminal fucose to N-glycans. Alternatively, it is possible that O-fucosyltransferases localize to subcellular compartments other than the Golgi apparatus with a different GDP-fucose transporter. Although O-FucT-1 has been proposed as a Golgi-resident protein (9) , no experimental evidence has been put forward to support this idea. Here we have examined the subcellular localization of O-FucT-1 protein and the EGF O-fucosylation reaction. Surprisingly, we found that O-FucT-1 is a soluble protein localized to the ER. Moreover, O-FucT-1 appears to catalyze the O-fucosylation reaction in the ER rather than the Golgi apparatus.
Materials and Methods
Materials -COS1 cells were from American Type Culture Collection (Rockville, MD). They were grown in DMEM media supplemented with 10% fetal bovine serum. Fractions from sucrose gradients of microsomes derived from rat liver were a kind gift from Drs. Michael Jadot (Facultés Universitaires Notre-Dame de la Paix) and Peter Lobel (Rutgers University). The procedures describing preparation of the sucrose gradients were previously described (27) . All other reagents were of the highest quality available. Immunofluorescent staining -COS1 cells growing on coverslips in 35mm dishes were transiently transfected with plasmids using LipofectAMINE 2000 (Invitrogen) following the manufacturer's protocol. After transfection (24 hours), cells were fixed in 3% paraformaldehyde in phosphate-buffered saline (PBS) and permeabilized with 0.1% Triton X-100 in PBS. Cells were then stained with mixtures of the following primary antibodies: mouse anti-HIS6 antibody (1:100) (Santa Cruz, Inc) and rabbit anti-calreticulin (1:500) (Stressgen); rabbit anti-HIS6 (1:100) (Santa Cruz, Inc) and mouse anti-GM130 (1:100) (BD Biosciences). Alexa fluor 488 and 568 conjugated secondary antibodies (Molecular Probes) were used at 1:100. Fluorescent images were collected using a Leica TCS SP2 confocal microscope.
Analysis of O-fucosylation on mouse Notch1
EGF29-36 -Preparation of the plasmid encoding EGF repeats 29-36 from mouse Notch1 with C-terminal MYC-HIS6-tags (pSecTag-EGF29-36), transfection, and metabolic radiolabeling with [ 3 H]fucose is described elsewhere (11) . After transfection (24 hours), COS1 cells were metabolically radiolabeled for another 24 hours. The media was removed and stored. The cells were washed three times with PBS and lysed in RIPA buffer (50mM Tris-HCl, pH8.0, 150mM NaCl, 1% NP40, 0.5% Deoxycholic Acid, 0.1% SDS) containing Protease Inhibitor Cocktail (Roche). EGF29-36 was purified from the cell lysates by immunoprecipitation using a rabbit anti-MYC antibody (Abcam) and Protein A-Sepharose, while EGF29-36 in the media was purified by Ni-NTA chromatography as described previously (11) . PNGase F digestion was performed on all the samples as described previously (24) and endoglycosidase H (Roche) digestion was carried out following the manufacturer's protocol. Western blots and fluorography were then performed as described (24) . Immunofluorescence of COS1 cells expressing EGF29-36 was performed as described above. Other methods -ß 4 G a l T assays and Ofucosyltransferase assays were performed as previously described (9, 28) .
Results
Endogenous O-FucT-1 appears to be a soluble protein in the ER. -In the original report of OFucT-1 purification, the enzyme was purified from a detergent-free extract of Chinese hamster ovary (CHO) cells (8) . Aminoterminal sequencing of the purified protein was performed, and the sequence was used to generate probes to isolate the gene encoding O-FucT-1 from a human heart cDNA library (9) . Interestingly, the predicted sequence of the human and mouse enzymes began approximately 20 residues amino-terminal to the sequence derived from the CHO cell enzyme ( Figure 1A) . Originally, we believed that this region encoded a short cytoplasmic domain and a transmembrane sequence, typical of the type II membrane structure found on all known mammalian Golgi glycosyltransferases (29) . Proteolytic loss of such sequences during purification has been reported previously (30) . Re-examination of the amino-terminal sequence from mouse and human O-FucT-1 u s i n g SMART (http://smart.embl-heidelberg . d e / ) or other sequence analysis tools suggests the previously predicted transmembrane sequence is actually a cleavable signal peptide ( Figure  1A) . Moreover, the sequenced amino terminus of purified O-FucT-1 begins at approximately the predicted cleavage site for the signal peptide ( Figure 1A) .
To confirm that O-FucT-1 is a soluble protein, COS1 cells were lysed by sonication and the activity of O-FucT-1 was assayed in high speed supernatant and pellet fractions. The majority of O-FucT-1 activity was found in supernatant ( Figure 1B) . As a control, we also compared the enzyme activity of a known membrane-bound protein, b4GalT, and found the majority of its activity in the pellet fraction ( Figure 1B) . These results strongly suggest that endogenous O-FucT-1 is a soluble protein.
All known fucosyltransferases responsible for terminal fucose modification on N-linked glycans are believed to be localized to the Golgi, consistent with the localization of the GDP-fucose transporter (1, (31) (32) (33) . However, the subcellular localization of O-FucT-1 is still unclear. Interestingly, N-glycans on purified O-FucT-1 from CHO cells are mostly high-mannose type oligosaccharide chains, suggesting this enzyme may be localized in either the ER or cis-Golgi region (8) . We sought to determine the localization of endogenous O-FucT-1 by sub-cellular fractionation of rat liver. Rat liver microsomes were fractionated on a sucrose gradient and assayed for O-FucT-1 activity, as well as markers for ER (glucose 6-phosphatase) and Golgi (b4GalT). The majority of the O-FucT-1 activity cofractionates with the ER marker (glucose 6-phosphatase), but not with the Golgi marker (b4GalT1) ( Figure 1C ). This result suggests that endogenous O-FucT-1 localizes to the ER. (Figure 2A ) (34) . We generated expression plasmids pSecTag-HIS6-O-FucT-1 a n d p S e c Tag-HIS6-O-FucT-1DRDEF, which encode N-terminal HIS6-tagged human O-FucT-1 with or without the KDEL-like motif, RDEF ( Figure 2B ). These two plasmids, as well as the empty pSecTag plasmid, were transiently transfected into COS1 cells. Western blot analysis of the media and lysate from the transfected cells using anti-HIS6 tag antibody revealed that O-FucT-1 with the RDEF motif is largely retained in the cells while O-FucT-1 without RDEF motif is largely secreted to the media ( Figure 2C ). To preclude the possibility that the observed difference in secretion is due to some effect on protein folding by the RDEF sequence, we performed activity assays on lysates of cells Figure 2C) . We t h e n c a r r i e d o u t immunofluorescent staining to determine the specific subcellular localization of HIS6-OFucT-1 and HIS6-O-FucT-1DRDEF in COS1 cells. The two expression plasmids were transiently transfected into COS1 cells on coverslips followed by staining using anti-HIS6 tag antibody along with either the ER marker anti-calreticulin antibody or the cisGolgi marker anti-GM130 antibody. The HIS6-O-FucT-1 displays a perinuclear and reticular distribution characteristic of ER, colocalizing with calreticulin but not with GM130 ( Figure 3A-F) . In contrast, deletion of RDEF results in a dramatic redistribution of cell associated O-FucT-1 including loss of colocalization with the calreticulin (Figure 3G-I ) and partial localization with the GM130 (Figure 3J-L) . The redistribution caused by deletion of the RDEF motif was even more dramatically observed in the Western blot analysis shown above demonstrating that the majority of HIS6-O-FucT-1DRDEF is secreted ( Figure 2C ). Taken together, the results suggest the C-terminal KDEL-like sequence functions as an ER retention/retrieval signal for O-FucT-1.
Addition of O-fucose to proteins appears to occur in the ER.
-Since GDP-fucose transporter activity has only been reported in Golgi fractions (31) , the localization of OFucT-1 to the ER raised the question of where addition of O-fucose to proteins occurs. To examine the subcellular site of O-fucosylation we used a previously reported plasmid encoding EGF repeats 29-36 from mouse Notch1 with C-terminal MYC and HIS6 tags that is secreted to the media (11). We chose this fragment because it has two predicted Nglycan sites as well as five predicted O-fucose sites ( Figure 4A ), and we have previously characterized its O-fucosylation (11) . Although EGF29-36 is secreted to the media, some of the protein can also be isolated from cell lysates. Immunostaining of COS1 cells transiently transfected with the EGF29-36 plasmid demonstrated that cell-associated EGF29-36 co-localizes with the ER marker calreticulin but not with the Golgi marker GM130 (Figure 4B-G) . This indicates that the vast majority of EGF29-36 within cells is in the ER. Control experiments demonstrated that more than 90% of the cell-associated EGF29-36 could be extracted from the cells using a RIPA lysis buffer (data not shown).
To examine O-fucosylation of EGF29-36, we metabolically radiolabeled COS1 cells expressing EGF29-36 with [ 3 H]fucose. Media and cells were separated, and EGF29-36 was purified from both (see Methods). Samples were digested with endoglycosidase H and PNGase F to evaluate the processing state of the attached N-glycans. Western blot and fluorographic analysis demonstrated that EGF29-36 retained in the cells is sensitive to endoglycosidase H digestion while secreted EGF29-36 is resistant ( Figure 4H, lanes 1, 2,  5, 6 ). This is consistent with the immunofluorescent staining data ( Figure 4B-D Figure 4H ) suggesting the presence of fucose on Nglycans being released by PNGaseF. This is consistent with fucosylation of N-glycans in the Golgi apparatus, which is well known (1,31-33) .
Finally, comparison of the stoichiometry of fucosylation after removal of the N-glycans with PNGase F (compare lanes 4 and 8, Figure 4H ) shows similar levels of 
Discussion
The recent studies on fucosylation in LADII/CDGIIc patients raised the intriguing question of how fucosylation of N-glycans could be almost completely eliminated while O-fucosylation remained unaffected (26) . Together with the previous report that O-FucT-1 bears N-glycans sensitive to endoglycosidase H (consistent with an ER or cis-Golgi localization) these results motivated us to examine the localization of O-FucT-1 in more detail. Using subcellular fractionation, we found that endogenous O-FucT-1 is a soluble protein localized in the ER. We next showed that the C-terminal KDEL-like motif (RDEF) of O-FucT-1 is responsible for retaining the protein in the ER. Immunofluorescent staining clearly demonstrated that expressed O-FucT-1 with the RDEF motif co-localizes with the ER marker calreticulin. Although we cannot completely rule out the possibility that some O-FucT-1 might localize within the Golgi, the amount appears to be relatively insignificant. Removal of the RDEF domain causes a dramatic change in O-FucT-1 localization. The majority of O-FucT-1DRDEF is secreted, and the small amount still associated with cells no longer co-localizes with calreticulin. These results strongly suggest that RDEF functions as an ER retention/retrieval signal.
We next addressed where O-FucT-1 catalyzes the O-fucosylation reaction. It is reasonable to speculate that the reaction occurs in the same compartment as the bulk of the enzyme, but this is in conflict with the fact that GDP-fucose transporter activity has historically been associated with the Golgi apparatus (31) . Immunofluorescent staining of COS1 cells transfected with a plasmid encoding mouse Notch1 EGF29-36 revealed that the vast majority of cell-associated EGF29-36 is localized to the ER. The Nglycans on this protein were sensitive to endoglycosidase H digestion, consistent with the ER localization. Surprisingly, this protein was also modified with O-fucose. Similar levels of fucosylation on EGF29-36 from cells (ER localized) and from the media indicated that O-fucosylation occurs in the ER. It is possible that EGF 29-36 could be Ofucosylated in the cis-Golgi and cycle back to the ER. This possibility would require that the bulk of EGF29-36 localized to the ER have already cycled through the cis-Golgi. Since EGF29-36 is being secreted and the net flow of the protein is through the Golgi, we think that this possibility is unlikely. Thus, we conclude that O-FucT-1 catalyzes the Ofucosylation reaction in the ER in contrast to all other known forms of fucosylation which occur in trans-Golgi or trans-Golgi network (1) .
GDP-fucose is the donor substrate for all known fucosyltransferases, including OFucT-1 (1). GDP-fucose is synthesized in the cytoplasm and is known to be transported into the Golgi lumen by a GDP-fucose transporter (31) . In order for O-FucT-1 to catalyze Ofucosylation in the ER lumen, some mechanism must exist that facilitates transport of GDP-fucose from the Golgi apparatus or cytoplasm. The studies on LADII/CDGIIc fibroblasts suggest that the Golgi of cells from these patients have insufficient GDP-fucose to account for a mechanism involving retrograde transport of GDP-fucose from the Golgi to the ER (14) . This would suggest that there is an unidentified GDP-fucose transporter localized in the ER. Historically, transporter assays using vesicles isolated from the ER or the Golgi have been used to demonstrate the presence of nucleotide sugar transporters (31) . GDP-fucose transporter activity has been detected in Golgi derived vesicles, but no evidence of transporter activity in ER derived vesicles has been reported. Our results predict that such a transporter may exist. Nonetheless, further work is necessary to evaluate whether GDP-fucose enters the ER through a novel transporter or a retrograde transport system.
The C-terminal KDEL-like sequence, RDEF, of human O-FucT-1 functions as an ER retention/retrieval signal. Similar sequences are found at the C-terminus of all known homologues of O-FucT-1 ( Figure 2A and data not shown). Aside from mammalian O-FucT-1, Drosophila O-FucT-1 has also been shown to localize to the ER (Okajima and Irvine, personal communication) .
Interestingly, deletion of the C-terminus of O-FucT-1 in Dro s o p h i l a causes a lethal phenotype, demonstrating the biological importance of ER retention/retrieval (16) . Thus, the ER localization appears to be critical to the function of O-FucT-1.
These results raise the question of why O-FucT-1 localizes to the ER. O-FucT-1 is known to recognize and fucosylate properly folded EGF repeats (8) . Thus, O-FucT-1 has the ability to distinguish between folded and unfolded EGF repeats. This observation, together with the ER localization of O-FucT-1, indicates O-fucosylation may serve as a quality control signal in the ER. Several possible models exist. For instance unknown escort proteins may recognize O-fucose and facilitate the transportation from the ER to the Golgi in a fashion analogous to recognition of N-glycans by ERGIC53 (34 
